Xizeng Hui

People’s Hospital of Rizhao

Papers

1

Total Citations

4

H-Index

1

About

Xizeng Hui is a leading clinical researcher in gastrointestinal oncology, with a focused expertise in the perioperative management of gastric cancer patients. His work centers on optimizing surgical outcomes through innovative, evidence-based interventions, particularly for patients with advanced disease. Dr. Hui’s major contribution is the design and leadership of the GISSG2023-01 Study, a landmark multicenter randomized controlled trial investigating the effect of perioperative probiotic supplements on short-term clinical outcomes following laparoscopic or robotic radical gastrectomy after neoadjuvant chemotherapy. This research addresses a critical gap in supportive care, aiming to mitigate the gut dysbiosis induced by chemotherapy and surgery to reduce complications and enhance recovery. His most cited paper (2025, 4 citations) has already garnered attention for its rigorous methodology and potential to reshape postoperative protocols. By integrating probiotics into the surgical pathway, Dr. Hui is pioneering a low-cost, high-impact strategy to improve prognoses for patients with advanced gastric cancer, demonstrating a commitment to translating mechanistic insights into tangible clinical benefits.

Research Focus

Key Achievements

1
H-Index
1
Papers
4
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Effect of perioperative probiotic supplements on the short-term clinical outcomes of patients undergoing laparoscopic or robotic radical gastrectomy after neoadjuvant chemotherapy: Study protocol for a multicenter randomized controlled trial (GISSG2023 - 01 Study)
4 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 25
🏛 Institutions: People’s Hospital of Rizhao

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago